Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment‐seeking cohort
The American Journal on Addictions · 2023-11 · 32 (6) · 547-553
DOI: 10.1111/ajad.13431 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal on Addictions, online erschienen am 02.05.2023. Verfasst von Nicholas L Bormann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Indiana University, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alcohol Drinking, Opioid-Related Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SAMHSA HHS, HRSA HHS, Substance Abuse and Mental Health Services Administration.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background and Objectives Comorbid substance use can negatively impact multiple aspects of treatment for patients with an opioid use disorder (OUD). We investigated if treatment for OUD led to improvements in patients' recovery capital (RC) overtime, and whether there were associated changes in co‐occurring alcohol use.
Methods
Participants ( n = 133) were patients with OUD seeking outpatient treatment, who completed the Assessment of Recovery Capital (ARC) and reported drinking days per 30‐day period thrice over the 6‐month study. No specific treatments targeting alcohol were used. Two different models were employed to assess changes in total ARC score and adjusted odds ratio (aOR) for past 30‐day abstinence.
Results
Baseline mean ARC scores were 36.6 and significantly increased to mean score of 41.2 at study end. Ninety‐one participants (68.4%) reported no alcohol use at baseline, and 97 (78.9%) reported no use in the previous 30 days at study endpoint. For each increase in ARC, there was an aOR 1.07 (confidence interval [CI]: 1.02–1.13) for past 30‐day abstinence. Considering ARC standard deviation of 10.33 over all measurements, this equates to an aOR of 2.10 (CI: 1.22–3.62) for past 30‐day abstinence. Discussion and Conclusions We saw significantly increased aOR for past 30‐day abstinence as RC improved in an OUD treatment‐seeking population. This difference was not caused by differences in ARC between study completers and noncompleters. Scientific Significance Showcases how RC growth may be protective of past 30‐day alcohol use in an OUD cohort and adds specific aOR for abstinence per ARC increase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Indiana University, Indianapolis, Indiana, USA.
- Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA.
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
- Department of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
- Department of Family Medicine, University of Iowa, Iowa City, Iowa, USA.
ORCID-Profile: Nicholas L Bormann, Andrea N Weber
Förderung
- SAMHSA HHS
- HRSA HHS
- Substance Abuse and Mental Health Services Administration
- Iowa Department of Public Health
- Health Resources and Services Administration
Zitieren
APA
Bormann, N. L., Weber, A. N., Arndt, S., & Lynch, A. (2023). Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment‐seeking cohort. The American Journal on Addictions, 32(6), 547-553. https://doi.org/10.1111/ajad.13431
Vancouver
Bormann NL, Weber AN, Arndt S, Lynch A. Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment‐seeking cohort. The American Journal on Addictions. 2023;32(6):547-553. doi:10.1111/ajad.13431
BibTeX
@article{Bormann2023,
author = {Bormann, Nicholas L and Weber, Andrea N and Arndt, Stephan and Lynch, Alison},
title = {Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment‐seeking cohort},
journal = {The American Journal on Addictions},
year = {2023},
volume = {32},
number = {6},
pages = {547--553},
doi = {10.1111/ajad.13431}
}
EUVIMED